BE863754A - NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS - Google Patents

NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS

Info

Publication number
BE863754A
BE863754A BE184992A BE184992A BE863754A BE 863754 A BE863754 A BE 863754A BE 184992 A BE184992 A BE 184992A BE 184992 A BE184992 A BE 184992A BE 863754 A BE863754 A BE 863754A
Authority
BE
Belgium
Prior art keywords
emi
vincamine
brain circulation
regulators
new
Prior art date
Application number
BE184992A
Other languages
French (fr)
Original Assignee
Dechamps Pierre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dechamps Pierre filed Critical Dechamps Pierre
Priority to BE184992A priority Critical patent/BE863754A/en
Publication of BE863754A publication Critical patent/BE863754A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D461/00Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

       

  Nouveaux dérivés de la vincamine utilisables comme régulateurs de la circulation cérébrale. 

  
 <EMI ID=1.1> 

  
Poudre microcristalline blanche de saveur amère, soluble dans l'eau et le méthanol, peu soluble dans les solvants organiques.

  

 <EMI ID=2.1> 


  
 <EMI ID=3.1> 

  
1. Spectre U.V. P.M. 701,23

  
 <EMI ID=4.1> 

  
à 263 nm = 305

  
2. Spectre I.R. (voir figure 1) - Pastille KBr à 3 %.

  
Le % de transmission se trouve en ordonnée ; la longueur d'onde en ? est donnée en abscisse, échelle supérieure et le nombre d'onde en cm , échelle inférieure.

  
Procédé de fabrication

  
On chauffe à reflux, sous atmosphère d'azote pendant 5 heures, 1 mole de vincamine avec 1 mole d'acide adénylique, dans 40 volumes de méthanol. On purifie par passage au noir décolorant la solution obtenue. Puis

  
on distille sous vide pour réduire la solution au quart de son volume. Après refroidissement, on essore le précipité, on le lave avec du méthanol et on le sèche sous vide à 40[deg.]C. 

  
 <EMI ID=5.1> 

  
Vasorégulation cérébrale de la vincamine complétée par l'action cardiotonique de l'acide adénylique. Toxicité :

  
La DL 100 per os est supérieure à 1 g/kg chez la souris.

  
 <EMI ID=6.1> 

  
Gélules de 20 à 40 mg 2 à 3 fois par jour. II. CODECARBOXYLATE DE VINCAMINE

  
Poudre microcristalline de couleur jaunâtre,

  
 <EMI ID=7.1> 

  

 <EMI ID=8.1> 


  
Identification :

  
1. Spectre U.V.

  
 <EMI ID=9.1> 

  
2. Spectre I.R. (voir figure 2) - Pastille KBr à 3 % Procédé de fabrication :

  
On chauffe à reflux pendant une heure sous atmosphère d'azote et bonne agitation, une mole de vincamine et une mole d'acide 5-pyridoxal-phosphorique dans

  
20 volumes de méthanol à 90 %.

  
On filtre la solution obtenue, concentre le filtrat sous vide au bain-marie et précipite le sel par  <EMI ID=10.1> 

  
Vasorégulation cérébrale de la vincamine complétée par l'action anti-scléreuse de la codêcarboxylase.

  
Toxicité 

  
La DL 100 per os est supérieure à 1 g/kg chez la souris.

  
 <EMI ID=11.1> 

  
Gélules de 20 à 40 mg 2 à 3 fois par jour.

REVENDICATIONS

  
1. Dérivé de vincamine constitué par l'adénylate de vincamine.

  
2. Dérivé de vincamine constitué par le codécarboxylate de vincamine.

  
3. Utilisation d'un dérivé de vincamine selon l'une quelconque des revendications 1 et 2 comme agent régulateur de la circulation cérébrale.



  New vincamine derivatives that can be used as regulators of cerebral circulation.

  
 <EMI ID = 1.1>

  
White microcrystalline powder with a bitter flavor, soluble in water and methanol, slightly soluble in organic solvents.

  

 <EMI ID = 2.1>


  
 <EMI ID = 3.1>

  
1. Spectrum U.V. P.M. 701.23

  
 <EMI ID = 4.1>

  
at 263 nm = 305

  
2. I.R. spectrum (see figure 1) - 3% KBr pellet.

  
The% transmission is on the ordinate; the wavelength in? is given on the abscissa, upper scale and the wave number in cm, lower scale.

  
Manufacturing process

  
1 mole of vincamine with 1 mole of adenylic acid is heated under reflux under a nitrogen atmosphere for 5 hours in 40 volumes of methanol. The solution obtained is purified by passing to decolorizing black. Then

  
it is distilled under vacuum to reduce the solution to a quarter of its volume. After cooling, the precipitate is filtered off, washed with methanol and dried under vacuum at 40.degree.

  
 <EMI ID = 5.1>

  
Cerebral vasoregulation of vincamine supplemented by the cardiotonic action of adenylic acid. Toxicity:

  
The LD 100 per os is greater than 1 g / kg in mice.

  
 <EMI ID = 6.1>

  
20 to 40 mg capsules 2 to 3 times a day. II. VINCAMINE CODECARBOXYLATE

  
Microcrystalline powder of yellowish color,

  
 <EMI ID = 7.1>

  

 <EMI ID = 8.1>


  
Identification :

  
1. U.V. spectrum

  
 <EMI ID = 9.1>

  
2. I.R. spectrum (see figure 2) - 3% KBr pellet Manufacturing process:

  
One mole of vincamine and one mole of 5-pyridoxal-phosphoric acid are heated under reflux for one hour under a nitrogen atmosphere and good stirring.

  
20 volumes of 90% methanol.

  
The solution obtained is filtered, the filtrate is concentrated under vacuum in a water bath and the salt is precipitated by <EMI ID = 10.1>

  
Cerebral vasoregulation of vincamine supplemented by the anti-sclerotic action of codecarboxylase.

  
Toxicity

  
The LD 100 per os is greater than 1 g / kg in mice.

  
 <EMI ID = 11.1>

  
20 to 40 mg capsules 2 to 3 times a day.

CLAIMS

  
1. Vincamine derivative consisting of vincamine adenylate.

  
2. Vincamine derivative consisting of vincamine codecarboxylate.

  
3. Use of a vincamine derivative according to any one of claims 1 and 2 as a regulating agent of cerebral circulation.


    

Claims (1)

4. Utilisation suivant la revendication 3, <EMI ID=12.1> 4. Use according to claim 3, <EMI ID = 12.1> administré par voie orale en doses de 20 à 40 mg 2 à 3 fois par jour pour obtenir une vasorëgulation cérébrale complétée par une action cardiotonique. administered orally in doses of 20 to 40 mg 2 to 3 times a day to achieve cerebral vasoregulation supplemented by cardiotonic action. 5. Utilisation suivant la revendication 3, 5. Use according to claim 3, <EMI ID=13.1> 6. Composition pharmaceutique appropriée <EMI ID = 13.1> 6. Appropriate pharmaceutical composition à une utilisation telle que définie dans les revendications <EMI ID=14.1> for use as defined in claims <EMI ID = 14.1> 7. Procédé de préparation d'un dérivé selon l'une quelconque des revendications 1 et 2, caractérisé en ce qu'on associe, dans des conditions de chauffage au reflux dans un alcool et sous une atmosphère d'azote,la vincamine avec une quantité équimoléculaire d'un réactif porteur d'un radical adénylique ou 5pyridoxal-phosphorique selon le composé final voulu. 7. A process for preparing a derivative according to any one of claims 1 and 2, characterized in that, under reflux heating conditions in an alcohol and under a nitrogen atmosphere, the vincamine is combined with a equimolecular amount of a reagent carrying an adenyl or 5pyridoxal-phosphoric radical depending on the desired final compound.
BE184992A 1978-02-08 1978-02-08 NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS BE863754A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BE184992A BE863754A (en) 1978-02-08 1978-02-08 NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE863754 1978-02-08
BE184992A BE863754A (en) 1978-02-08 1978-02-08 NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS

Publications (1)

Publication Number Publication Date
BE863754A true BE863754A (en) 1978-05-29

Family

ID=25650570

Family Applications (1)

Application Number Title Priority Date Filing Date
BE184992A BE863754A (en) 1978-02-08 1978-02-08 NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS

Country Status (1)

Country Link
BE (1) BE863754A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183002A1 (en) * 1984-10-26 1986-06-04 Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. Pharmaceutically active salt derivative of 3-hydroxy -5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
US6417204B1 (en) 2000-07-07 2002-07-09 Medicure International Inc. Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
US6605612B2 (en) 2000-02-29 2003-08-12 Medicure International Inc. Cardioprotective phosohonates and malonates
US6677356B1 (en) 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US7812037B2 (en) 2004-10-28 2010-10-12 Medicure International, Inc. Dual antiplatelet/anticoagulant pyridoxine analogs

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183002A1 (en) * 1984-10-26 1986-06-04 Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. Pharmaceutically active salt derivative of 3-hydroxy -5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6890943B2 (en) 1999-03-08 2005-05-10 Medicure Inc. Pyridoxal analogues and methods of treatment
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
US7230009B2 (en) 1999-03-08 2007-06-12 Medicure, Inc. Pyridoxal analogues and methods of treatment
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
US7148233B2 (en) 1999-08-24 2006-12-12 Merrill Lynch Capital Canada Inc. Treatment of cardiovascular and related pathologies
US7144892B2 (en) 1999-08-24 2006-12-05 Merrill Lynch Capital Canada Inc. Treatment of cardiovascular and related pathologies
US7132430B2 (en) 1999-08-24 2006-11-07 Medicure International Inc. Treatment of cardiovascular and related pathologies
US7125889B2 (en) 1999-08-24 2006-10-24 Medicure International Inc. Treating of cardiovascular and related pathologies
US6677356B1 (en) 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
US7115626B2 (en) 1999-08-24 2006-10-03 Medicure International Inc. Treatment of cardiovascular and related pathologies
US7105673B2 (en) 2000-02-29 2006-09-12 Medicure International Inc. Cardioprotective phosphonates and malonates
US6867215B2 (en) 2000-02-29 2005-03-15 Medicure International Inc. Cardioprotective phosphonates and malonates
US6780997B2 (en) 2000-02-29 2004-08-24 Medicure International Inc. Cardioprotective phosphonates and malonates
US6667315B2 (en) 2000-02-29 2003-12-23 Medicure International Inc. Cardioprotective phosphonates and malonates
US6605612B2 (en) 2000-02-29 2003-08-12 Medicure International Inc. Cardioprotective phosohonates and malonates
US6861439B2 (en) 2000-03-28 2005-03-01 Medicure International, Inc. Treatment of cerebrovascular disease
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6417204B1 (en) 2000-07-07 2002-07-09 Medicure International Inc. Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US7812037B2 (en) 2004-10-28 2010-10-12 Medicure International, Inc. Dual antiplatelet/anticoagulant pyridoxine analogs

Similar Documents

Publication Publication Date Title
BE863754A (en) NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS
CH624952A5 (en)
BE1000573A4 (en) DERIVATIVES 1- (hydroxystyryl) -5 H 2,3-BENZODIAZEPINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING.
SU1122224A3 (en) Method of obtaining 4-oxy-2-methyl-n-2-pyridyl-2h-1,2-benzthiazine-3-carboxamide-1,1-dioxide
FR2464957A1 (en) PSORALENES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CH641181A5 (en) INDOLO-QUINOLIZIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM.
CA1310326C (en) Process for the preparation of 1-hydroxy-5-nitroimidazoles
EP0200605A1 (en) Nitrofuran derivatives, their preparation and their therapeutical use
SU1454253A3 (en) Method of producing 9-(2-oxyethoxymethyl) guanine
CH662118A5 (en) CHLORO-4-FURO- (3,4-C) -PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS BASED ON SUCH DERIVATIVES.
EP0021991A1 (en) Cystamine derivatives, their preparation and pharmaceutical compositions containing them
FR2478094A1 (en) AMMONIO SUBSTITUTED CINNAMYLMORANOLINE DERIVATIVES WITH INHIBITION ACTIVITY OF SUGAR LEVEL IN BLOOD
CH645115A5 (en) PROCESS FOR PREPARING CHLORO-7 METHYL-2 DIHYDRO-3,3A 2H, 9H-ISOXAZOLO (3,2-B) (BENZOXAZINE-1,3) ONE-9.
BE884977A (en) NOVEL N-PHENYL-BENZAMIDES USEFUL IN THE TREATMENT OF MAMMALIAN INFLAMMATION AND PAIN
EP0646579A1 (en) Ketonic indane derivatives and heterocyclic analysis and their use in therapy
FR2487347A1 (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED DIALURIC ACIDS IN POSITION 5
EP0390673A1 (en) 5-Acyl-benzoxazolinone derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0022022A1 (en) Acylated derivatives of taurine and their salts, and process for their preparation
CH622251A5 (en)
EP0646574B1 (en) Ketonic indane derivatives, their preparation and therapeutic application thereof
CH650255A5 (en) IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
FR2563224A1 (en) NEW BORNANE DERIVATIVES AND THEIR PREPARATION PROCESS
BE633582A (en)
BE537081A (en)
BE862600A (en) NEW ALKALOID PAMOATES